Cytomegalovirus restricts ICOSL expression on antigen presenting cells disabling T cell co-stimulation and contributing to immune evasion

  1. Guillem Angulo
  2. Jelena Zeleznjak
  3. Pablo Martínez-Vicente
  4. Joan Puñet-Ortiz
  5. Hartmut Hengel
  6. Martin Messerle
  7. Annette Oxenius
  8. Stipan Jonjic
  9. Astrid Krmpotic
  10. Pablo Engel
  11. Ana Angulo  Is a corresponding author
  1. University of Barcelona, Spain
  2. University of Rijeka, Croatia
  3. Albert-Ludwigs-Universität Freiburg, Faculty of Medicine, Germany
  4. Hannover Medical School, Germany
  5. ETH Zürich, Switzerland
  6. Faculty of Medicine and Health Sciences, University of Barcelona, Spain

Abstract

Viral infections are controlled, and very often cleared, by activated T lymphocytes. The inducible co-stimulator (ICOS) mediates its functions by binding to its ligand ICOSL, enhancing T-cell activation and optimal germinal center (GC) formation. Here, we show that ICOSL is heavily downmodulated during infection of antigen presenting cells by different herpesviruses. We found that, in murine cytomegalovirus (MCMV), the immunoevasin m138/fcr-1 physically interacts with ICOSL, impeding its maturation and promoting its lysosomal degradation. This viral protein counteracts T-cell responses, in an ICOS-dependent manner, and limits virus control during the acute MCMV infection. Additionally, we report that blockade of ICOSL in MCMV-infected mice critically regulates the production of MCMV-specific antibodies due to a reduction of T follicular helper and GC B cells. Altogether, these findings reveal a novel mechanism evolved by MCMV to counteract adaptive immune surveillance, and demonstrates a role of the ICOS:ICOSL axis in the host defense against herpesviruses.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files

Article and author information

Author details

  1. Guillem Angulo

    Biomedical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7086-9754
  2. Jelena Zeleznjak

    Center for Proteomics / Department of Histology and Embryology, University of Rijeka, Rijeka, Croatia
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6619-3675
  3. Pablo Martínez-Vicente

    Biomedical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain
    Competing interests
    No competing interests declared.
  4. Joan Puñet-Ortiz

    Biomedical Sciences, University of Medicine, University of Barcelona, Barcelona, Spain
    Competing interests
    No competing interests declared.
  5. Hartmut Hengel

    Institute of Virology, Albert-Ludwigs-Universität Freiburg, Faculty of Medicine, Freiburg, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3482-816X
  6. Martin Messerle

    Institute of Virology, Hannover Medical School, Hannover, Germany
    Competing interests
    No competing interests declared.
  7. Annette Oxenius

    Institute of Microbiology, Department of Biology, ETH Zürich, Zürich, Switzerland
    Competing interests
    No competing interests declared.
  8. Stipan Jonjic

    Deparment of Histology and Embryology, University of Rijeka, Rijeka, Croatia
    Competing interests
    Stipan Jonjic, Reviewing editor, eLife.
  9. Astrid Krmpotic

    Department of Histology and Embryology, University of Rijeka, Rijeka, Croatia
    Competing interests
    No competing interests declared.
  10. Pablo Engel

    Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
    Competing interests
    No competing interests declared.
  11. Ana Angulo

    Biomedical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain
    For correspondence
    aangulo@ub.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5792-1164

Funding

Ministerio de Economía y Competitividad (SAF 2017-87688)

  • Ana Angulo

Ministerio de Economía y Competitividad (RTI2018-094440-B-I00)

  • Pablo Engel

European Regional Development Fund (KK.01.1.1.01.0006)

  • Stipan Jonjic

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. John W Schoggins, University of Texas Southwestern Medical Center, United States

Ethics

Animal experimentation: All procedures involving animals and their care were approved (protocol number CEEA 308/12) by the Ethics Committee of the University of Barcelona (Spain) and the Animal Welfare Committee at the University of Rijeka (Croatia) and were conducted in compliance with institutional guidelines as well as with national (Generalitat de Catalunya decree 214/1997, DOGC 2450) and international (Guide for the Care and Use of Laboratory Animals, National Institutes of Health, 85-23, 1985) laws and policies.

Human subjects: Human blood was obtained from healthy volunteer donors through the Blood and Tissue Bank of the Catalan Department of Health (Barcelona, Spain). Utilization of blood products for the experiments conducted was approved by the Ethics Committee of the Hospital Clinic of Barcelona (Barcelona, Spain), and according to the principles of the Declaration of Helsinki.

Version history

  1. Received: May 27, 2020
  2. Accepted: January 15, 2021
  3. Accepted Manuscript published: January 18, 2021 (version 1)
  4. Version of Record published: January 27, 2021 (version 2)
  5. Version of Record updated: February 25, 2021 (version 3)

Copyright

© 2021, Angulo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,154
    views
  • 181
    downloads
  • 5
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Guillem Angulo
  2. Jelena Zeleznjak
  3. Pablo Martínez-Vicente
  4. Joan Puñet-Ortiz
  5. Hartmut Hengel
  6. Martin Messerle
  7. Annette Oxenius
  8. Stipan Jonjic
  9. Astrid Krmpotic
  10. Pablo Engel
  11. Ana Angulo
(2021)
Cytomegalovirus restricts ICOSL expression on antigen presenting cells disabling T cell co-stimulation and contributing to immune evasion
eLife 10:e59350.
https://doi.org/10.7554/eLife.59350

Share this article

https://doi.org/10.7554/eLife.59350

Further reading

    1. Immunology and Inflammation
    Thomas Morgan Li, Victoria Zyulina ... Theresa T Lu
    Research Article Updated

    The autoimmune disease lupus erythematosus (lupus) is characterized by photosensitivity, where even ambient ultraviolet radiation (UVR) exposure can lead to development of inflammatory skin lesions. We have previously shown that Langerhans cells (LCs) limit keratinocyte apoptosis and photosensitivity via a disintegrin and metalloprotease 17 (ADAM17)-mediated release of epidermal growth factor receptor (EGFR) ligands and that LC ADAM17 sheddase activity is reduced in lupus. Here, we sought to understand how the lupus skin environment contributes to LC ADAM17 dysfunction and, in the process, differentiate between effects on LC ADAM17 sheddase function, LC ADAM17 expression, and LC numbers. We show through transcriptomic analysis a shared IFN-rich environment in non-lesional skin across human lupus and three murine models: MRL/lpr, B6.Sle1yaa, and imiquimod (IMQ) mice. IFN-I inhibits LC ADAM17 sheddase activity in murine and human LCs, and IFNAR blockade in lupus model mice restores LC ADAM17 sheddase activity, all without consistent effects on LC ADAM17 protein expression or LC numbers. Anti-IFNAR-mediated LC ADAM17 sheddase function restoration is associated with reduced photosensitive responses that are dependent on EGFR signaling and LC ADAM17. Reactive oxygen species (ROS) is a known mediator of ADAM17 activity; we show that UVR-induced LC ROS production is reduced in lupus model mice, restored by anti-IFNAR, and is cytoplasmic in origin. Our findings suggest that IFN-I promotes photosensitivity at least in part by inhibiting UVR-induced LC ADAM17 sheddase function and raise the possibility that anifrolumab ameliorates lupus skin disease in part by restoring this function. This work provides insight into IFN-I-mediated disease mechanisms, LC regulation, and a potential mechanism of action for anifrolumab in lupus.

    1. Immunology and Inflammation
    Xiaochan Xu, Bjarke Frost Nielsen, Kim Sneppen
    Research Article

    SARS-CoV-2 induces delayed type-I/III interferon production, allowing it to escape the early innate immune response. The delay has been attributed to a deficiency in the ability of cells to sense viral replication upon infection, which in turn hampers activation of the antiviral state in bystander cells. Here, we introduce a cellular automaton model to investigate the spatiotemporal spreading of viral infection as a function of virus and host-dependent parameters. The model suggests that the considerable person-to-person heterogeneity in SARS-CoV-2 infections is a consequence of high sensitivity to slight variations in biological parameters near a critical threshold. It further suggests that within-host viral proliferation can be curtailed by the presence of remarkably few cells that are primed for IFN production. Thus, the observed heterogeneity in defense readiness of cells reflects a remarkably cost-efficient strategy for protection.